SCHEMBL6789513

SCHEMBL6789513

Cc1cc(Cl)ccc1C#CCCCO

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.44
▸ PGK1 P00558 4/20 0.43
▸ KDM4E B2RXH2 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ PTGDR2 Q9Y5Y4 1/20 0.34
▸ GABRP O00591 1/20 0.33
▸ GABRD O14764 1/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ GABRB1 P18505 1/20 0.33
▸ GABRG2 P18507 1/20 0.33
▸ GABRB3 P28472 1/20 0.33
▸ GABRA5 P31644 1/20 0.33
▸ GABRA3 P34903 1/20 0.33
▸ GABRA2 P47869 1/20 0.33
▸ GABRB2 P47870 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6788689 0.87 PTGDR2 (0.44) PGK1KDM4EMAPTCYP3A4ALDH1A1
SCHEMBL6304363 0.83 CYP3A4 (0.42) PGK1KDM4EMAPTCYP3A4ALDH1A1
SCHEMBL6297668 0.83 PGK1 (0.48) PGK1KDM4EMAPTCYP3A4ALDH1A1
SCHEMBL6791668 0.82 ALDH1A1 (0.41) PGK1KDM4EMAPTCYP3A4ALDH1A1
SCHEMBL6298783 0.81 FFAR1 (0.43) FFAR1PGK1MAPTCYP3A4PTGDR2
SCHEMBL12115806 0.81 ALDH1A1 (0.47) PGK1KDM4EMAPTCYP3A4ALDH1A1
SCHEMBL12185498 0.81 KDM4E (0.41) PGK1KDM4EMAPTCYP3A4ALDH1A1
SCHEMBL6297687 0.80 PGK1 (0.48) PGK1KDM4EMAPTCYP3A4ALDH1A1
SCHEMBL7203454 0.78 RARB (0.40) PGK1KDM4EMAPTCYP3A4ALDH1A1
SCHEMBL14374021 0.77 KDM4E (0.44) PGK1KDM4EMAPTCYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6784184-B2 FOR THERAPY OF RAS- ONCOGENE-DEPENDENT TUMORS, SUCH AS CANCERS OF PANCREAS, COLON, BLADDER, AND THYROID; USEFUL FOR CONTROLLING METASTASIS, SUPPRESSING ANGIOGENESIS, INDUCING APOPTOSIS, AND RAS-ASSOCIATED PROLIFERATIVE DISEASES WYETH HOLDINGS CORPORATION 2004-08-31 — — US disclosed
US-6605628-B1 Treatment of ras oncogene-dependent tumors; controlling metastasis, suppressing angiogenesis, inducing apoptosis WYETH HOLDINGS CORPORATION 2003-08-12 — — US disclosed
Send feedback